GM
Genesis Molecular AI, founded in 2019, builds foundation models and platforms such as GEMS and Pearl for molecular AI, targeting difficult protein problems in drug discovery and development.
Hummingbird Bioscience
Hummingbird Bioscience is a precision biotherapeutics company using AI to develop transformative medicines for hard-to-treat diseases.
Hummingbird Bioscience is a precision biotherapeutics company that employs artificial intelligence and innovation to discover and develop transformative medicines for hard-to-treat diseases, with a focus on oncology and autoimmunity.
The company's technical expertise spans Artificial Intelligence, Computational Biology, Systems Biology, and Antibody Engineering. Its product pipeline includes candidates such as HMBD-001, an anti-HER3 antibody, HMBD-002, an anti-VISTA monoclonal antibody, and HMBD-501, a next-generation HER3-targeted ADC.
Hummingbird Bioscience secured Series C funding of US$125 million and operates with a presence in Singapore and Texas, USA.
Open jobs
No open jobs right now.